Skip to main content
Springer Nature Link
Log in
Menu
Find a journal Publish with us Track your research
Search
Saved research
Cart
  1. Home
  2. Psychopharmacology
  3. Article

Clinical effects and plasma levels of Δ9-Tetrahydrocannabinol (Δ9-THC) in heavy and light users of cannabis

  • Original Investigations
  • Published: July 1981
  • Volume 74, pages 208–212 (1981)
  • Cite this article

Access provided by Institution of Civil Engineers Library

Download PDF
Save article
View saved research
Psychopharmacology Aims and scope Submit manuscript
Clinical effects and plasma levels of Δ9-Tetrahydrocannabinol (Δ9-THC) in heavy and light users of cannabis
Download PDF
  • Jan-Erik Lindgren1,
  • Agneta Ohlsson2,
  • Stig Agurell1,2,
  • Leo Hollister3 &
  • …
  • Hamp Gillespie3 
  • 675 Accesses

  • 134 Citations

  • 13 Altmetric

  • Explore all metrics

Abstract

Δ9-Tetrahydrocannabinol (Δ9-THC) was administered in a crossover design by smoking and IV injection to groups of heavy and light users of marihuana. Plasma concentrations of Δ9-THC were similar for the groups after IV injection of 5.0 mg Δ9-THC, but the AUC0–240 min showed a trend towards lower values for the heavy user group. To achieve a maximum desired “high”, both groups smoked similar amounts (about 13 mg) of Δ9-THC. Heavy users tended to have higher plasma levels than light users. The systemic availability of smoked Δ9-THC was significantly higher for the heavy users (heavy users 23±16% vs 10±7% for light users). These results also indicate that heavy cannabis users smoke more efficiently than casual smokers.

Both light and heavy users showed more clinical effect following IV administration than after smoking. The response of the heavy users, both with respect to effect on heart and “high”, was quite comparable to that of light users.

The present study does not suggest that tolerance readily develops in heavy users.

Article PDF

Download to read the full article text

Similar content being viewed by others

Hexahydrocannabinol (HHC) and Δ9-tetrahydrocannabinol (Δ9-THC) driven activation of cannabinoid receptor 1 results in biased intracellular signaling

Article Open access 22 April 2024

Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies

Article Open access 07 July 2022

Smokeless consumption of medical cannabis pharmacokinetics, safety and feasibility of the CannaHALER© a phase 1a study

Article Open access 26 March 2020

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.
  • Drug Screening
  • Drugs
  • Narcotic
  • Psychoactive Drug
  • Toxicology

Refrences

  • Benowitz NL, Jones RT (1977) Effects of Δ9-tetrahydrocannabinol on drug distribution and metabolism. Clin Pharmacol Ther 22:259–268

    Google Scholar 

  • Hollister LE (1973) Cannabidiol and cannabinol in man. Experientia 29:825–826

    Google Scholar 

  • Hollister LE (1979) Cannabis and the development of tolerance. In: Nahas G, Paton WDM (eds) Marihuana: Biological effects. Pergamon Press, London, pp 585–589

    Google Scholar 

  • Hollister LE, Kanter SL, Moore F, Green DE (1972) Marihuana metabolites in urine of man. Clin Pharmacol Ther 13:849–855

    Google Scholar 

  • Lemberger L, Rubin A (1976) Physiologic disposition of drugs of abuse. Spectrum Publications, New York, pp 269–310

    Google Scholar 

  • Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970) Marihuana: Studies on the disposition and metabolism of Δ9-tetrahydrocannabinol in man. Science 170:1320–1322

    Google Scholar 

  • Ohlsson A, Lindgren JE, Wahlén A, Agurell S, Hollister LE, Gillespie H (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416

    Google Scholar 

  • Perez-Reyes M, Timmons MC, Wall ME (1974) Long-term use of marihuana and the development of tolerance or sensitivity to Δ9-tetrahydrocannabinol. Arch Gen Psychiatry 31:89–91

    Google Scholar 

  • Willette RE, ed. (1976) Cannabinoid assays in humans. NIDA Research Monograph 7. National Institute on Drug Abuse, Rockville

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Astra läkemedel AB, S-151 85, Södertälje, Sweden

    Jan-Erik Lindgren & Stig Agurell

  2. Department of Pharmacology, Karolinska Institute, S-104 01, Stockholm, Sweden

    Agneta Ohlsson & Stig Agurell

  3. Veterans Administration Hospital, 3801 Miranda Avenue, 94304, Palo Alto, CA, USA

    Leo Hollister & Hamp Gillespie

Authors
  1. Jan-Erik Lindgren
    View author publications

    Search author on:PubMed Google Scholar

  2. Agneta Ohlsson
    View author publications

    Search author on:PubMed Google Scholar

  3. Stig Agurell
    View author publications

    Search author on:PubMed Google Scholar

  4. Leo Hollister
    View author publications

    Search author on:PubMed Google Scholar

  5. Hamp Gillespie
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindgren, JE., Ohlsson, A., Agurell, S. et al. Clinical effects and plasma levels of Δ9-Tetrahydrocannabinol (Δ9-THC) in heavy and light users of cannabis. Psychopharmacology 74, 208–212 (1981). https://doi.org/10.1007/BF00427095

Download citation

  • Received: 10 October 1980

  • Accepted: 20 February 1981

  • Issue date: July 1981

  • DOI: https://doi.org/10.1007/BF00427095

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Key words

  • Δ9-Tetrahydrocannabinol
  • Pharmacokinetics
  • Plasma levels
  • Marihuana
  • Cannabis

Advertisement

Search

Navigation

  • Find a journal
  • Publish with us
  • Track your research

Footer Navigation

Discover content

  • Journals A-Z
  • Books A-Z

Publish with us

  • Journal finder
  • Publish your research
  • Language editing
  • Open access publishing

Products and services

  • Our products
  • Librarians
  • Societies
  • Partners and advertisers

Our brands

  • Springer
  • Nature Portfolio
  • BMC
  • Palgrave Macmillan
  • Apress
  • Discover

Corporate Navigation

  • Your US state privacy rights
  • Accessibility statement
  • Terms and conditions
  • Privacy policy
  • Help and support
  • Legal notice
  • Cancel contracts here

172.71.28.157

ICE Institution of Civil Engineers (3000167333) - Institution of Civil Engineers Library (2000027800)

Springer Nature

© 2026 Springer Nature